Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (August 30th Preview)
-
FDA approvals and trial readouts in cardiometabolic disease
The FDA has approved Eli Lilly’s tirzepatide (Mounjaro) to reduce cardiovascular risk in adults with type 2 diabetes, based on results from SURPASS-CVOT. The outcomes trial compared tirzepatide head-to-head with dulaglutide and showed non-inferiority for major adverse cardiovascular events (MACE-3). The decision adds another indication to a drug already established for glycemic control and weight loss. The FDA action follows growing scrutiny and interest in CV outcomes across incretin-based therapies, particularly as manufacturers broaden labels to earlier lines of intervention.
-
FDA clearance and rapid development for rare inflammatory disorders
Roivant’s Priovant Therapeutics received FDA clearance for Lisraya (brepocitinib) to treat adults with dermatomyositis, marking another label win in a fast-moving rare-inflammation pipeline. The approval positions the once-daily oral JAK1/TYK2 inhibitor beyond earlier rare disease efforts and expands use for patients with an immunologic drivers profile. The regulatory step comes as competing cytokine-signaling approaches continue to mature, with JAK pathway modulation remaining central to multiple late-stage programs across rare autoimmune indications.
-
Immunotherapy pipeline expansion via ADC deals
DualityBio and Genentech (Roche) entered a collaboration and license agreement to develop next-generation antibody-drug conjugates built around DualityBio’s DUPAC payload platform. The deal includes $45 million upfront and milestone payments that could exceed $1 billion, with tiered royalties. DualityBio will lead discovery and early-stage global clinical development through Phase I, while Genentech will take over broader clinical development and commercialization. The arrangement targets resistance to older topoisomerase inhibitor payloads and aims to improve activity in earlier-line settings where unmet need is rising.
-
Regulatory fast-track for an EpCAM-directed conditional ADC in colorectal cancer
The FDA granted fast track designation to CytomX’s varsetatug masetecan (Varseta-M; CX-2051), an EpCAM-directed masked, conditionally activated antibody-drug conjugate, for relapsed or refractory metastatic colorectal cancer. The designation is based on Phase 1 dose-expansion results from the CTMX-2051-101 trial. Across expansion doses, confirmed objective response rates ranged from 6% to 32%, with a disease control rate of 88% overall. Diarrhea was the most common treatment-related adverse event, including grade 3 events in a subset receiving an updated prophylactic regimen.
-
Fundraising to advance ASO therapy for chronic hepatitis B
AusperBio raised $120 million in a Series C round to advance its oligonucleotide therapy for chronic hepatitis B through Phase 3 and beyond. The company’s strategy focuses on moving an oligo program with a defined clinical path toward registration while scaling capabilities for later-stage trials. The financing highlights continued capital commitment to nucleic-acid approaches in HBV, even as the field seeks therapies that more effectively suppress viral persistence and improve functional outcomes.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.